Life-threatening thrombocytosis following GCSF treatment in a case of clozapine-induced agranulocytosis

详细信息	查看全文 | 推荐本文 |

• 作者：Sabita Dihingia ; M.D.^a ; Kamala Deka ; M.D.^a ; Dhrubajyoti Bhuyan ; M.D.^a ; Supriya Kumar Mondal ; M.D.^b ; ^{supriya007007@yahoo.co.in}
• 关键词：Clozapine ; Agranulocytosis ; G-CSF ; Thrombocytosis
• 刊名：General Hospital Psychiatry
• 出版年：2012
• 期刊代码：107_01638343
• 类别：med
• 出版时间：May-June, 2012
• 卷：34
• 期：3
• 页码：320.e1-320.e2
• 文件大小：143 K

摘要

Clozapine was introduced in European market in 1972 as an effective treatment for schizophrenia without extrapyramidal side effects. Within a short while, the clozapine story virtually came to a halt following detection of life-threatening neutropenia and agranulocytosis. Judicial use of granulocyte colony stimulating factor (GCSF) can be life saving with infrequent side effects in these cases. Here we are presenting a case of clozapine induced agranulocytosis managed with GCSF but had transient but life-threatening thrombocytosis, a very uncommon complication of GCSF therapy. Expression of GCSF receptors on the surface of megakaryocytic lineage is thought to be the cause of this unusual phenomenon.